Novartis
Global pharmaceutical company delivering science-based innovations
Principal Scientist 2 – Translational Biomarker Strategy Lead
+ Performance-based bonus
About the job
- A PhD, MD, PharmD, or equivalent degree in biology, pharmacology, immunology, translational medicine, molecular biology, or a related discipline is required.
- At least 7 years of experience in translational research, biomarker strategy, biomarker discovery, or drug development within the pharmaceutical or biotechnology industry is required.
- Demonstrated experience developing biomarker strategies that support drug discovery and development programs is required.
- Strong understanding of biomarker applications, including target engagement, pharmacodynamics, patient stratification, disease activity, and mechanism-based biomarkers is required.
- Experience leading cross-functional matrix teams and influencing scientific strategy without direct authority is required.
- Excellent communication, presentation, and stakeholder management skills are required.
- Lead the development of stage-appropriate preclinical and translational biomarker strategies for DAx programs from target validation through early clinical development readiness.
- Serve as the biomarker representative and single point of contact on assigned DAx project teams.
- Define biomarker hypotheses, context of use, evidence requirements, and decision criteria aligned with program milestones.
- Develop integrated biomarker plans encompassing assays, models, samples, analyses, timelines, and external partnerships.
- Partner across Biology, In Vitro, In Vivo, Data Science, Preclinical Safety, Quantitative Sciences, Translational Medicine, and Biomarker Development to align biomarker activities and execution.
- Generate translational evidence linking target biology, pharmacology, and biomarkers to support key portfolio decisions.
- Drive external collaborations and leverage innovative technologies, datasets, and human sample resources to strengthen biomarker strategies and the research-to-development transition.
About the company
Novartis is a global pharmaceutical company that uses science-based innovations to develop treatments and improve patient outcomes worldwide. Its products are medicines developed through research and development to address various diseases, aiming to reach nearly 1 billion people. The company differentiates itself by large-scale investment in R&D, a global presence with a diverse workforce, and a clear mission to Reimagine Medicine, focusing on meeting the changing needs of patients. Its goal is to improve quality of life and extend life expectancy by delivering meaningful therapies through its research and development efforts.
Company Size
10,001+
Company Stage
IPO
Headquarters
Basel, Switzerland
Founded
1970
Get referred to Novartis
See people who can refer or advise you
Simplify's Take
What believers are saying
- REMODEL-1 and REMODEL-2 met endpoints for remibrutinib on September 1, 2026.
- CHMP backed Cosentyx for polymyalgia rheumatica on September 18, 2026.
- Novartis invested in AI training for 6,000 U.S. employees on September 16, 2026.
What critics are saying
- Pelacarsen failed Lp(a)HORIZON on September 4, 2026, erasing a cardiovascular blockbuster.
- Del-desiran failed HARBOR on September 8, 2026, challenging the Avidity acquisition thesis.
- Entresto, about 10% of sales, faces generic erosion after 2028 and U.S. litigation.
What makes Novartis unique
- Novartis dominates radioligand therapy, adding BoomRay's global license on September 22, 2026.
- Novartis controls Entresto exclusivity through 2028 SPC victories in London, August 13, 2026.
- Novartis bought Sironax's blood-brain-barrier platform, strengthening CNS delivery on September 16, 2026.
Help us improve and share your feedback! Did you find this helpful?
Benefits
Health Insurance
Dental Insurance
Vision Insurance
Life Insurance
Disability Insurance
401(k) Retirement Plan
401(k) Company Match
Paid Vacation
Paid Sick Leave
Paid Holidays
Hybrid Work Options
Growth & Insights and Company News
6 month growth
↓ -3%1 year growth
↓ -3%2 year growth
↓ -3%Lantheus Holdings wins FDA approval for Bravnetsa before Curium vote. The adult GEP-NET radiopharmaceutical is therapeutically equivalent to Lutathera, but Lantheus has not announced its launch date or price. The U.S. list of approved treatments for adults with somatostatin receptor-positive gastroenteropancreatic neuroendocrine tumours grew on Tuesday after Lantheus Holdings, Inc. NASDAQLNTH said the FDA granted final approval to Bravnetsa, a radiopharmaceutical equivalent to Lutathera. The decision moves abbreviated application 217060 beyond tentative approval, giving Lantheus an approved adult cancer therapy as it prepares for a vote on its sale to privately held Curium. The company's release says Bravnetsa, previously called PNT2003, was approved under an abbreviated new drug application after the FDA found it bioequivalent and therapeutically equivalent to the reference product Lutathera. Lantheus did not announce a launch date or price. Lantheus is a Bedford, Massachusetts, developer and seller of radiopharmaceutical imaging agents and cancer treatments, with a pending sale to Curium. Lantheus shares NASDAQLNTH closed unchanged at US$100.00 on Nasdaq at 4 p.m. EDT on Sept. 22, the day of the announcement. A Sept. 8 merger proxy says Curium would pay US$102.50 a share in cash at closing, with additional contingent payments possible if specified sales targets are met. Adult label leaves launch timing open. The FDA's Feb. 27, 2026, tentative-approval letter identified the application as ANDA 217060 and found Bravnetsa equivalent to the reference product. The September final decision authorizes marketing for adults with receptor-positive tumours of the pancreas or gastrointestinal tract, including foregut, midgut and hindgut disease. It is an equivalence finding, not evidence that Bravnetsa outperforms Lutathera. The adult-only label has a boundary: Lutathera also carries a pediatric indication, but Bravnetsa's prescribing information omits that use because of the reference maker's pediatric marketing exclusivity. The approval therefore gives Lantheus access to the adult market without extending its label to children. Bravnetsa's safety information warns of cumulative radiation exposure, bone-marrow suppression and kidney injury. Those are labeling warnings for lutetium Lu 177 dotatate treatment; the release presented no new clinical comparison with Lutathera. "We are focused on a thoughtful launch and ensuring the right commercial and operational capabilities are in place to support reliable supply and broad patient access," Lantheus executive chair and chief executive Mary Anne Heino said in the release. The incumbent, Novartis AG SWXNOVN NYSENVS, reported US$225 million in Lutathera sales for the second quarter of 2026. That July 21 figure gives a measure of the existing market, though Lantheus has not disclosed a revenue forecast for Bravnetsa. Mugglehead previously covered a separate Novartis actinium-based cancer drug trial. Curium received FDA approval on Sept. 14 for Bexlutry, another adult GEP-NET treatment using lutetium Lu 177 dotatate, and said it was already available. Curium's product came through a separate 505(b)(2) application supported by bridging data, while Bravnetsa has the agency's explicit therapeutic-equivalence determination under an abbreviated application. Among listed developers, Perspective Therapeutics, Inc. NYSEAMERICANCATX is testing a different radioactive medicine against somatostatin receptor-positive neuroendocrine tumours. The company scheduled updated VMT-alpha-NET data for Oct. 23 at the ESMO Congress; that program remains investigational. The iShares Biotechnology ETF NASDAQIBB closed at US$210.81 on Sept. 22 at 4 p.m. EDT, up 1.76 per cent that day. The benchmark's movement provides sector context for the Sept. 22 session. The Curium vote is next. The merger proxy sets US$102.50 per share as the cash consideration and up to US$12 more through contingent value rights. Its specified sales milestones cover prostate cancer diagnostics, neurology diagnostics and the DEFINITY ultrasound product. Bravnetsa is outside those defined groups, so this approval does not itself trigger a contingent payment. Curium's own Bexlutry approval means the proposed buyer and Lantheus now hold separate U.S. authorizations for treatments aimed at the same adult GEP-NET population. The companies have not said how they would position the two products together if the transaction closes, which is expected in the first half of 2027 subject to conditions. Lantheus shareholders are scheduled to vote on the Curium merger on Oct. 14. That vote will decide whether the agreed cash-and-contingent-rights transaction can proceed while the timing and terms of Bravnetsa's launch remain undisclosed.
Wednesday newspaper round-up: state pension, pharmaceutical companies, BMW. Share Search You are here: 23rd Sep 2026 07:05 (Sharecast News) - A thinktank linked to Reform UK has called for the abolition of the state pension and £75bn worth of sweeping tax cuts in a "radical" report likely to influence the party's platform for the next election. The Centre for a Better Britain's (CFABB) report - which also calls for weaker rules for UK banks and Trump-style investment accounts offering £1,000 to newborns - will be formally launched at a private event with City executives on Wednesday. - Guardian Motorists buying a secondhand car with a lot of miles on the clock are likely to find an electric vehicle (EV) ultimately more reliable than a petrol vehicle, according to a study. An analysis of 47.4m MOT tests found that after cars were driven 90,000 to 120,000 miles, EVs were about 25% less likely to fail than petrol models of the same age (based on a failure rate of 16.5% versus 22.1%). Beyond 120,000 miles, 16% of EVs failed, compared with 23.5% of petrol cars. The study found relatively little difference between the two fuel types at lower mileages. - Guardian Britain's biggest pharmaceutical companies have warned the future of the industry is at risk as Europe loses ground to the US and China in medical research. AstraZeneca and GSK, along with European rivals Novo Nordisk, Sanofi, Roche and Novartis, wrote an open letter warning that they were "losing ground to global competition". The letter warned that "without urgent action, strategic sectors like pharmaceuticals face a 'slow agony' of decline" as rivals increasingly dominate research-and-development spending and investment. - Telegraph BMW is facing a bill of more than £600m from the motor finance mis-selling scandal, marking one of the biggest hits faced by any lender. In newly filed accounts, the German carmaker's British finance arm increased its provision to cover mis-selling claims from £206m in 2024 to £612m in 2025. BMW's liability is more than the £430m that Barclays expects to pay and the £320m set aside by Close Brothers, another major car finance lender. However, it is still dwarfed by the worst affected lender, Lloyds Banking Group, which has provisioned £1.95bn. - Telegraph The state-backed British Business Bank and NatWest have agreed a "watershed" deal to invest in Phoenix Court, one of the UK's leading venture capital firms. The investment is the latest stage in efforts to get British capital into promising businesses to help them grow. The British Business Bank and NatWest will invest in Phoenix Court funds alongside HSBC and M&G. It is the first time that NatWest has invested in a venture capital fund. HSBC and M&G have invested in previous Phoenix Court funds. - The Times
Amgen's autoimmune drug succeeds in late-stage trial. Tue, September 22, 2026 at 6:01 AM PDT Sept 22 (Reuters) - Amgen said on Tuesday its experimental drug to treat an autoimmune disease that attacks the body's moisture-producing glands met the main goal of reducing disease activity in a late-stage trial. Here are some details: - The drug dazodalibep showed statistically significant and clinically meaningful improvement in patients with Sjogren's disease at week 48. - Sjogren's disease can cause extensive dryness of the eyes, mouth and other parts of the body, along with fatigue and chronic pain. - It affects about 1% of the global population and predominantly affects women, according to the National Institutes of Health. - Amgen said most adverse events in the trial were mild to moderate, with few patients discontinuing treatment. - Novartis and Johnson & Johnson are also developing drugs to treat Sjogren's disease, which has no approved treatments in the US. - Amgen plans to present detailed data from the trial at an upcoming medical meeting. The trial is expected to be completed in the fourth quarter of 2026. (Reporting by Christy Santhosh in Bengaluru; Editing by Vijay Kishore)
MSL: Publicis Groupe's global PR network agency profile. MSL is Publicis Groupe's global public relations and integrated communications network, with more than 3,100 people across 107-plus offices worldwide. Diana Littman has served as CEO of MSL U.S. since December 2018, reporting to Publicis Groupe chairman and CEO Arthur Sadoun. What is MSL? MSL is Publicis Groupe's public relations and integrated communications network, one of the largest PR networks operating in Europe and, according to the firm, the fastest growing PR network in Asia Pacific. The network provides strategic counsel and creative campaign work across corporate communications, consumer marketing, social purpose and sustainability, employee communications, crisis, technology, health, and food and beverage practices. How did MSL originate? MSL traces its roots to 1980, when the agency then known as MS&L was acquired by advertising agency Benton & Bowles. Benton & Bowles later merged with Leo Burnett before the combined group was acquired by France's Publicis Groupe, folding MSL into what is now the world's third largest communications company. The network absorbed Schwartz Communications, a Waltham, Massachusetts public relations firm founded in 1990, after Publicis Groupe acquired it in 2011 and fully merged it into MSLGROUP by 2014. Who leads MSL U.S. and when did she join? Publicis Groupe announced Diana Littman as CEO of MSL U.S. on November 1, 2018, with Littman formally joining that December. She reports directly to Arthur Sadoun, Publicis Groupe's chairman and CEO, and also sits on the Publicis Groupe USA Executive Committee. Her mandate at appointment was to elevate public relations, influence marketing, and earned engagement inside Publicis Groupe's integrated model. Littman brought a decade at Marina Maher Communications and a prior decade at Cohn & Wolfe to the MSL role. Her oversight spans MSL's offices in Atlanta, Boston, Chicago, Detroit, New York, Seattle, and Washington, D.C. Arthur Sadoun said at her appointment that building brand influence that drives client impact is more critical today than ever. Which clients and sectors does MSL serve? MSL's client work spans consumer, healthcare, and corporate reputation accounts. The Institute for Public Relations lists MSL's client partners as including Procter & Gamble, GM, Eli Lilly, Inspire Brands, J.M. Smucker, Gilead, and KitchenAid. MSL and Novartis won the Cannes Lions Grand Prix in 2026, and the network brought Procter & Gamble's Mr. Clean campaign to Cannes Lions the same year. What awards has MSL won? MSL was named 2025 SABRE Global Agency of the Year and appeared on the 2026 MM+M Agency 100 list. Littman's own career recognitions, accumulated across her time at MSL, Marina Maher Communications, and Cohn & Wolfe, include multiple SABRE, Effie, Cannes Lions, PRWeek, and MM&M awards, along with Holmes Report Agency of the Year honors. 5WPR: 25 Years Of ExcellencePublic Relations Agency | Media, Marketing and AI Search Talk to [email protected] How is MSL organized globally? MSL organizes leadership by country CEO across markets including the United Kingdom, France, Germany, South Africa, and the United Arab Emirates, a structure the network describes internally as a Power of One collaborative model within Publicis Groupe. Country leaders named by the network include Rebecca Grant, CEO of Publicis PSI U.K., and Liza Zhang, CEO of MSL China. Where does MSL fit among global PR networks? MSL competes at the top tier of holding company PR networks alongside Edelman, the world's largest independent, and the PR arms of the other major holding companies, including WPP's Ogilvy PR and Havas Red. Within Publicis Groupe specifically, MSL sits inside Publicis Communications, the group's creative hub, alongside advertising agencies Publicis Worldwide, Saatchi & Saatchi, Leo Burnett, BBH, Marcel, and Fallon. MSL's scale, more than 3,100 staff across over 107 offices, puts it in direct competition for the largest global corporate and consumer accounts that require simultaneous campaign execution across dozens of markets, a category of work that boutique and mid-market independents are generally not staffed to handle. How has MSL grown through acquisitions? Beyond the Schwartz Communications merger, MSL's growth has come substantially through Publicis Groupe's wider acquisition strategy for its communications arm. The network's documented history includes a 2010 acquisition of Indian technology and social media firm 20:20 and an acquisition of Chinese firm Eastwei Relations the same year, expanding MSL's footprint into two of the fastest growing PR markets globally at the time. Frequently asked questions. MSL is Publicis Groupe's public relations and integrated communications network, one of the largest PR networks operating in Europe and, according to the firm, the fastest growing PR network in Asia Pacific. The network provides strategic counsel and creative campaign work across corporate communications, consumer marketing, social purpose and sustainability, employee communications, crisis, technology, health, and food and beverage practices. MSL traces its roots to 1980, when the agency then known as MS&L was acquired by advertising agency Benton & Bowles. Benton & Bowles later merged with Leo Burnett before the combined group was acquired by France's Publicis Groupe, folding MSL into what is now the world's third largest communications company. The network absorbed Schwartz Communications, a Waltham, Massachusetts public relations firm founded in 1990, after Publicis Groupe acquired it in 2011 and fully merged it into MSLGROUP by 2014. Publicis Groupe announced Diana Littman as CEO of MSL U.S. on November 1, 2018, with Littman formally joining that December. She reports directly to Arthur Sadoun, Publicis Groupe's chairman and CEO, and also sits on the Publicis Groupe USA Executive Committee. Her mandate at appointment was to elevate public relations, influence marketing, and earned engagement inside Publicis Groupe's integrated model. Littman brought a decade at Marina Maher Communications and a prior decade at Cohn & Wolfe to the MSL role. Her oversight spans MSL's offices in Atlanta, Boston, Chicago, Detroit, New York, Seattle, and Washington, D.C. Arthur Sadoun said at her appointment that building brand influence that drives client impact is more critical today than ever. MSL's client work spans consumer, healthcare, and corporate reputation accounts. The Institute for Public Relations lists MSL's client partners as including Procter & Gamble, GM, Eli Lilly, Inspire Brands, J.M. Smucker, Gilead, and KitchenAid. MSL and Novartis won the Cannes Lions Grand Prix in 2026, and the network brought Procter & Gamble's Mr. Clean campaign to Cannes Lions the same year. MSL was named 2025 SABRE Global Agency of the Year and appeared on the 2026 MM+M Agency 100 list. Littman's own career recognitions, accumulated across her time at MSL, Marina Maher Communications, and Cohn & Wolfe, include multiple SABRE, Effie, Cannes Lions, PRWeek, and MM&M awards, along with Holmes Report Agency of the Year honors. MSL organizes leadership by country CEO across markets including the United Kingdom, France, Germany, South Africa, and the United Arab Emirates, a structure the network describes internally as a Power of One collaborative model within Publicis Groupe. Country leaders named by the network include Rebecca Grant, CEO of Publicis PSI U.K., and Liza Zhang, CEO of MSL China. MSL competes at the top tier of holding company PR networks alongside Edelman, the world's largest independent, and the PR arms of the other major holding companies, including WPP's Ogilvy PR and Havas Red. Within Publicis Groupe specifically, MSL sits inside Publicis Communications, the group's creative hub, alongside advertising agencies Publicis Worldwide, Saatchi & Saatchi, Leo Burnett, BBH, Marcel, and Fallon. MSL's scale, more than 3,100 staff across over 107 offices, puts it in direct competition for the largest global corporate and consumer accounts that require simultaneous campaign execution across dozens of markets, a category of work that boutique and mid-market independents are generally not staffed to handle. Beyond the Schwartz Communications merger, MSL's growth has come substantially through Publicis Groupe's wider acquisition strategy for its communications arm. The network's documented history includes a 2010 acquisition of Indian technology and social media firm 20:20 and an acquisition of Chinese firm Eastwei Relations the same year, expanding MSL's footprint into two of the fastest growing PR markets globally at the time. When was MSL founded? MSL traces its lineage to 1980, when MS&L was acquired by Benton & Bowles, ahead of Publicis Groupe's later acquisition of the combined agency group. Who is the CEO of MSL U.S.? Diana Littman, appointed November 2018 and in place since December 2018, reporting to Publicis Groupe chairman and CEO Arthur Sadoun. How large is MSL? More than 3,100 people across more than 107 offices worldwide, per Publicis Groupe's own announcement materials. What does MSL specialize in? Public relations, reputation management, cultural intelligence and influence campaigns, and integrated communications for global and regional clients across consumer, healthcare, and corporate reputation work. Editorial assessment by Everything-PR, based on public record and archive coverage. No firm-supplied marketing copy, no paid placement. Related agency profiles: Kekst CNC agency profile Full PR agency profiles directory EPR Editorial Team The Everything-PR Editorial Team produces original reporting, research, and analysis on communications, reputation, AI visibility, and digital discovery in the answer-engine era - built to be cited by the AI engines that now answer the question. Publishing since 2009. From AI Visibility
BoomRay inks global radiopharma license deal with Novartis. 22 September 2026 China-based clinical-stage company BoomRay Pharmaceuticals today announced that it has entered into an exclusive global license agreement with Novartis (NOVN: VX) for an undisclosed pre-clinical RLT asset, marking yet another radiopharmaceuticals deal for the Swiss pharma giant. The agreement brings together BoomRay's discovery and development capabilities with the global expertise of Novartis in the RLT space, to pursue the goal of delivering meaningful therapeutic benefit to patients worldwide. This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here. Try before you buy Free. 7 day trial access * All the news that moves the needle in pharma and biotech * Exclusive features, podcasts, interviews, data analyses and commentary from its global network of life sciences reporters. * Receive The Pharma Letter daily news bulletin, free forever. Become a subscriber £820. Or £77 per month * Unfettered access to industry-leading news, commentary and analysis in pharma and biotech. * Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results. * Daily roundup of key events in pharma and biotech. * Monthly in-depth briefings on Boardroom appointments and M&A news. * Choose from a cost-effective annual package or a flexible monthly subscription The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It's part of the key information for keeping me informed Chairman, Sanofi Aventis UK More on this story... 3 September 2026 2 September 2026 17 July 2026 Company news directory. Companies featured in this story. Sign up to receive email updates Join industry leaders for a daily roundup of biotech & pharma news Today's issue. 22 September 2026 Company spotlight. A commercial-stage Australian biopharmaceutical company building a vertically integrated theranostics franchise across prostate cancer, renal cell carcinoma, and neuro-oncology through FDA-approved PSMA imaging agents and an advancing radiotherapeutic pipeline. More features in pharmaceutical. 22 September 2026